A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously

NCT00427453 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Oxford